CoChat

Fundamental immune–oncogenicity trade-offs define driver mutation fitness

Open access
Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, Greenbaum, Benjamin D. · 2022 · Nature
Cited by 80

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Missense driver mutations in cancer are concentrated in a few hotspots 1. Various mechanisms have been proposed to explain this skew, including biased mutational processes 2, phenotypic differences 3–6 and immunoediting of neoantigens 7,8; however, to our knowledge, no existing model weighs the relative contribution of these features to tumour evolution. We propose a unified theoretical ‘free fitness’ framework that parsimoniously integrates multimodal genomic, epigenetic, transcriptomic and proteomic data into a biophysical model of the rate-limiting processes underlying the fitness advantage conferred on cancer cells by driver gene mutations. Focusing on TP53, the most mutated gene in cancer 1, we present an inference of mutant p53 concentration and demonstrate that TP53 hotspot mutations optimally solve an evolutionary trade-off between oncogenic potential and neoantigen immunogenicity. Our model anticipates patient survival in The Cancer Genome Atlas and patients with lung cancer treated with immunotherapy as well as the age of tumour onset in germline carriers of TP53 variants. The predicted differential immunogenicity between hotspot mutations was validated experimentally in patients with cancer and in a unique large dataset of healthy individuals. Our data indicate that immune selective pressure on TP53 mutations has a smaller role in non-cancerous lesions than in tumours, suggesting that targeted immunotherapy may offer an early prophylactic opportunity for the former. Determining the relative contribution of immunogenicity and oncogenic function to the selective advantage of hotspot mutations thus has important implications for both precision immunotherapies and our understanding of tumour evolution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-04696-z

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 80

Metadata

Authors
Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K. C., Bajorin, D. F., Bandlamudi, C., Callahan, M. K., Funt, S. A., Hadrup, S. R., Holm, J. S., Rosenberg, J. E., Shah, S. P., Vázquez-García, I., Weigelt, B., Wu, M., Zamarin, D., Campitelli, L. F., Osborne, E. J., Klinger, M., Robins, H. S., Khincha, P. P., Savage, S. A., Balachandran, V. P., Wolchok, J. D., Hellmann, M. D., Merghoub, T., Levine, A. J., Łuksza, M., & Greenbaum, B. D.
Venue
Nature
Published
2022-05-11
Volume
606
Issue
7912
Pages
172-179
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4280534777
Cited by
80
References
11
FWCI
5.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fundamental immune–oncogenicity trade-offs define driver mutation fitness. https://app.cochat.ai/papers/10.1038/s41586-022-04696-z
The paper
Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K. C., Bajorin, D. F., Bandlamudi, C., Callahan, M. K., Funt, S. A., Hadrup, S. R., Holm, J. S., Rosenberg, J. E., Shah, S. P., Vázquez-García, I., Weigelt, B., Wu, M., Zamarin, D., Campitelli, L. F., Osborne, E. J., . . . Greenbaum, B. D. (2022). Fundamental immune–oncogenicity trade-offs define driver mutation fitness. Nature. https://doi.org/10.1038/s41586-022-04696-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.